hydrocodone bitartrate and homatropine methylbromide

FDA Drug Profile — Hydromet

hydrocodone bitartrate and homatropine methylbromide is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Hydromet. Available dosage form: solution.

Drug details

Generic Name
hydrocodone bitartrate and homatropine methylbromide
Brand Names
Hydromet
Application Number
ANDA088017
Sponsor
Actavis Pharma, Inc.
NDC Codes
1
Dosage Forms
SOLUTION
Routes
ORAL
Active Ingredients
HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE

Indications and Usage

1 INDICATIONS AND USAGE Hydrocodone bitartrate and homatropine methylbromide is indicated for the symptomatic relief of cough in adult patients 18 years of age and older. Limitations of Use : Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)] . Contraindicated in pediatric patients less than 6 years of age [see Contraindications (4)] . Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy [see Warnings and Precautions (5.1)] , reserve hydrocodone bitartrate and homatropine methylbromide for use in adult patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of cough. Hydrocodone bitartrate and homatropine methylbromide is a combination of hydrocodone, an opioid agonist; and homatropine, a muscarinic antagonist, indicated for the symptomatic relief of cough in adult patients 18 years of age and older. (1) Limitations of Use Not indicated for pediatric patients under 18 years of age. (1) Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve hydrocodone bitartrate and homatropine methylbromide for use in adult patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of cough. (1, 5.1)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.